Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Colorcon
McKesson
Boehringer Ingelheim
McKinsey

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR FERRIC PYROPHOSPHATE CITRATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ferric Pyrophosphate Citrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02595437 ↗ Triferic Pediatric Pharmacokinetic Protocol Completed Rockwell Medical Technologies, Inc. Phase 1/Phase 2 2015-11-01 The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.
NCT02636049 ↗ Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers Completed Rockwell Medical Technologies, Inc. Phase 1 2015-10-01 This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
NCT02739100 ↗ Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Completed Rockwell Medical Technologies, Inc. Phase 1 2016-04-01 The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered via hemodialysate and via two different intravenous routes in adult patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, randomized single dose study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ferric Pyrophosphate Citrate

Condition Name

Condition Name for Ferric Pyrophosphate Citrate
Intervention Trials
End Stage Renal Disease 7
Iron-refractory, Iron-deficiency Anemia (IRIDA) 1
Peritoneal Dialysis (PD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ferric Pyrophosphate Citrate
Intervention Trials
Kidney Failure, Chronic 7
Anemia, Iron-Deficiency 3
Kidney Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ferric Pyrophosphate Citrate

Trials by Country

Trials by Country for Ferric Pyrophosphate Citrate
Location Trials
United States 21
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ferric Pyrophosphate Citrate
Location Trials
Florida 5
Michigan 2
Texas 2
Ohio 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ferric Pyrophosphate Citrate

Clinical Trial Phase

Clinical Trial Phase for Ferric Pyrophosphate Citrate
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1/Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ferric Pyrophosphate Citrate
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ferric Pyrophosphate Citrate

Sponsor Name

Sponsor Name for Ferric Pyrophosphate Citrate
Sponsor Trials
Rockwell Medical Technologies, Inc. 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ferric Pyrophosphate Citrate
Sponsor Trials
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
McKinsey
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.